Aehr Test Systems (AEHR) Price Prediction 2026: Can Record Bookings Push AEHR Stock to $125?

Aehr Test Systems (AEHR) reported fiscal 2026 fourth-quarter results on July 14, 2026 that improved from the prior-year period. Revenue was $18.8 million, quarterly bookings reached a record $60.7 million, and the company reported $100.6 million of effective backlog after the May 29 quarter-end. Management guided fiscal 2027 revenue to $130 million to $150 million. AEHR closed at $103.07 on August 7, 2026, after a 410.50% year-to-date move.

The results were not the whole question. Backlog validates demand visibility, but it does not establish when customer qualification, installation and acceptance will become revenue and cash flow. Fiscal 2026 revenue declined to $50.0 million and operating cash flow was negative, so the next reports must confirm a durable delivery and margin bridge.

The AEHR stock forecast for 2026 now centers on two competing views:

The production-conversion case: Record bookings, an effective backlog of $100.6 million and fiscal 2027 guidance could support a higher valuation if quarterly delivery and margin evidence follow.
The execution-risk case: Revenue recognition, customer concentration and negative fiscal 2026 operating cash flow could matter more than backlog if production ramps shift out.

This guide breaks down the AEHR stock forecast, 2026 price scenarios, key risks and dated analyst actions, plus how to trade AEHR stock futures on BingX TradFi with USDT collateral.

Top 5 Things for Aehr Test Systems Investors to Know in August 2026

Record $60.7 million bookings create the fiscal 2027 starting point: Aehr reported bookings more than three times its $18.8 million fiscal Q4 revenue. The investment issue has shifted from demand discovery to revenue conversion and shipment timing.
Effective backlog reached $100.6 million after the May 29 quarter-end: The figure includes $80.6 million of reported backlog and subsequent bookings. It gives management a base for its forecast, but it is not the same as recognized revenue.
Fiscal 2027 revenue guidance implies a sharp scale change: The $130 million to $150 million range represents approximately 160% to 200% growth from fiscal 2026 revenue of $50.0 million. Execution must be visible in reported quarterly delivery and margin progress.
Fiscal Q4 showed a quarterly inflection, not a completed annual turnaround: Q4 revenue was $18.8 million and GAAP net income was $1.4 million, versus $14.1 million of revenue and a $2.9 million loss a year earlier. Full-year fiscal 2026 still recorded a $7.1 million GAAP loss.
AEHR closed at $103.07 on August 7 after a 410.50% YTD move: The available $117.50 consensus reference and $125 Street high leave the market focused on whether guidance becomes results rather than whether AI demand exists in principle.

Trade Aehr Test Systems (AEHR) on BingX

What Is Aehr Test Systems (AEHR)?

Aehr Test Systems (NASDAQ: AEHR) is a semiconductor test, burn-in, and stabilization-equipment company. Its FOX platforms, WaferPak contactors, and Sonoma systems are used to test semiconductor devices at the wafer, die, and package levels, helping manufacturers identify reliability problems before chips move into later production stages. Its addressable applications include AI processors, silicon photonics, power semiconductors, memory, and other infrastructure-related devices where reliability and thermal performance are especially important.

Aehr is particularly known for wafer-level burn-in, which allows manufacturers to detect defects before more expensive packaging and system-integration steps. In its July 14 earnings, the company highlighted customer activity in wafer-level AI accelerator testing, high-power package-level burn-in for AI processors, silicon photonics, and silicon-carbide applications. These represent several distinct growth paths for Aehr, but each still depends on customer evaluations progressing into production deployments, equipment orders, and ultimately recognized revenue.

Aehr Test Systems Fiscal 2026 Fourth-Quarter Earnings: What Drove Record Bookings and the Delivery Debate

Revenue and profitability improved in the final quarter. Fiscal Q4 revenue was $18.8 million, up from $14.1 million in fiscal Q4 2025. GAAP net income was $1.4 million, or $0.04 per diluted share, compared with a $2.9 million loss, or $0.10 per diluted share.
Bookings were the central new data point. The $60.7 million quarterly total supported an $80.6 million backlog at May 29 and $100.6 million effective backlog including later bookings. The distinction matters because backlog is a visibility measure, not an earnings measure.
Management set a measurable fiscal 2027 operating bridge. The company guided for $130 million to $150 million in revenue and non-GAAP net income equal to 18% to 22% of revenue. That makes revenue conversion and non-GAAP margin delivery the two report-card variables.
AI and photonics are prospective production-ramp drivers. Management described increased needs from a lead AI production customer, pilot-validation interest from another top-tier AI processor supplier and activity from silicon-photonics customers. These comments explain the opportunity; they do not establish that every program will ship on the same schedule.
SiC adds diversification but remains a separate recovery test. Aehr cited approximately $8 million of silicon-carbide WaferPak orders in its July 14, 2026 release and expects renewed SiC and GaN demand. Automotive and power-infrastructure timing can still diverge from the AI cycle.

Aehr Test Systems Q4 2026 Financial and Consensus Profile: Revenue, EPS and Margins

Aehr's Q4 print showed a quarterly recovery alongside the central question of whether record bookings can become revenue, cash flow and durable margin expansion.

Financial Metric	Consensus Estimate	Reported / Actual	Surprise
Fiscal Q4 revenue	—	$18.8 million	Improved. Up 33.3% year over year.
Fiscal Q4 bookings	—	$60.7 million	Record. Order intake drives the fiscal 2027 conversion thesis.
Effective backlog	—	$100.6 million	Visibility. Includes bookings after May 29.
Fiscal Q4 GAAP net income	—	$1.4 million	Improved. Reversed from a loss a year earlier.
Fiscal Q4 GAAP diluted EPS	—	$0.04	Improved. Reversed from a $0.10 loss per diluted share.
Fiscal 2026 operating cash flow	—	-$3.3 million	Negative. Cash conversion remains a fiscal 2027 watchpoint.
Fiscal 2027 revenue guidance	—	$130 million to $150 million	Forward guide. Approximately 160% to 200% growth versus fiscal 2026.

For context, fiscal 2026 revenue declined to $50.0 million from $59.0 million while the company used $3.3 million in operating cash. That annual contrast is why the stock's valuation depends more on repeatable conversion evidence than on one strong bookings quarter.

Aehr Test Systems (AEHR) 2026 Investment Outlook: $125 Bull Case vs. $60 Bear Case

Aehr's outlook for the rest of 2026 depends on one central question: whether record bookings and AI-related production programs become reported revenue fast enough to validate fiscal 2027 guidance, or whether delivery timing and concentration risk delay that conversion.

The Bull Case: AI Production Conversion Pushes AEHR Toward $125

The bullish case needs the current effective backlog to become revenue without meaningful customer-installation or qualification delays. Evidence supporting that case includes record bookings, the company's reported AI customer activity and management's $130 million to $150 million fiscal 2027 revenue guide.

A close toward the $125 aggregate Street high would require investors to see guidance credibility in quarterly revenue, shipment progress and non-GAAP profitability. It would also require the AI, silicon-photonics and SiC programs to broaden rather than leave the company dependent on a narrow set of ramps.

The Base Case: Strong Demand but Uneven Delivery Keeps AEHR Between $85 and $110

The base case assumes growth converts, but not in a straight line. Backlog can provide a starting point while system installation, customer qualification and the timing of consumables revenue produce uneven quarters. That outcome would keep the market focused on proof of delivery rather than on the full value of the guide.

The $85 to $110 article range is not a Wall Street target. It reflects a scenario in which the company demonstrates meaningful growth but leaves an evidence gap around the timing, customer concentration and margin durability needed for a sustained premium valuation.

The Bear Case: Backlog Conversion Pressure Pulls AEHR Toward $60

The bear case does not require AI testing demand to disappear. It requires a delay in the programs that support the fiscal 2027 bridge, exposing the gap between booked demand and recognized revenue.

The $60 to $75 article range is a valuation sensitivity, not an analyst forecast. Observable bear-case signals would include weak backlog conversion, a reduction in the fiscal 2027 revenue range, margin pressure or customer production schedules moving out.

AEHR Stock Price Forecasts for 2026 By Wall Street Analysts

Coverage of Aehr is thin, as is typical for a small-cap equipment name, but the July fiscal Q4 report drove a rapid, unified re-rating higher, with multiple firms raising targets and ratings within days. Earlier 2026 rating actions, taken before the Q4 turnaround, are now dated and reflect the weaker mid-year outlook rather than the current picture.

Institution	2026 Price Target	Rating	Market Outlook
Craig-Hallum / Christian Schwab	$125	Buy	Street high. Raised from $68, sees revenue nearly tripling by fiscal 2027.
Lake Street	$110	Buy	Bullish. Doubled its target on AI data center and photonics demand.
Freedom Broker	$110	Buy	Bullish. Upgraded from Hold, calling fiscal 2026 the long-awaited inflection.
Wall Street consensus	~$115	Strong Buy	Bullish. Constructive across a small group of covering analysts.
William Blair	Not disclosed	Outperform	Positive. Upgraded from Market Perform on the AI evaluation progress.
Article bear scenario	$60 to $75	Bear case	Editorial. A conditional scenario, excluded from the Street consensus.
Article Bear scenario Article prediction, not a Street target	$60 to $75	Bear	Editorial. This conditional article scenario is excluded from the Wall Street consensus and analyst-action count.

How to Trade Aehr Test Systems (AEHR) Stock on BingX

Navigate the volatility of Aehr Test Systems' earnings cycle using BingX TradFi and BingX AI tools. AEHR-USDT is a TradFi perpetual market route, so it provides derivative exposure rather than ownership of a listed Aehr share or a Spot token. Leverage, funding and liquidation can amplify losses.

Step 1: Access BingX TradFi. Sign up and navigate to the specialized TradFi section on the main BingX exchange dashboard.

Step 2: Select Aehr Test Systems (AEHR). Search for and select the AEHR-USDT perpetual futures contract on BingX TradFi.

Step 3: Choose your direction. Select Open Long if you expect AI accelerator testing, silicon photonics, and semiconductor burn-in demand to translate into stronger orders and revenue growth. Select Open Short if customer evaluations take longer to convert, semiconductor equipment spending weakens, or the stock's valuation moves ahead of confirmed revenue growth.

Step 4: Select leverage and margin mode. Choose Isolated or Cross-Margin based on your risk tolerance. AEHR can move sharply around earnings, customer announcements, and changes in AI or semiconductor demand, so conservative leverage and clear position sizing are important.

Step 5: Execute strict risk protocols. Set Take-Profit and Stop-Loss (TP/SL) levels before or immediately after entering the trade. AEHR can react quickly to earnings guidance, new AI accelerator orders, silicon photonics deployments, silicon-carbide demand, customer qualification progress, and changes in semiconductor capital spending.

Trade Aehr Test Systems (AEHR) on BingX

Top 5 Risks to Watch for Aehr Test Systems Investors in 2026

Fiscal 2027 guidance requires 160% to 200% revenue growth: The $130 million to $150 million range is ambitious relative to fiscal 2026 revenue of $50.0 million. Qualification, installation or customer-ramp delays can materially change the market's view of guide credibility.
Effective backlog is not recognized revenue: The $100.6 million figure supports visibility, but delivery schedules and acceptance timing determine when it becomes reported revenue and cash.
Fiscal 2026 operating cash flow was negative: Aehr used $3.3 million in operating cash during fiscal 2026. A durable turnaround needs working-capital and cash conversion to improve alongside revenue.
Production programs may create customer concentration exposure: Management described lead AI, hyperscale, photonics and SiC customer activity. A timing shift at a lead program can have an outsized effect on a company of Aehr's reported revenue scale.
AEHR has already repriced sharply in 2026: The stock closed at $103.07 on August 7 after a 410.50% YTD move. High expectations can create volatility when operational milestones fall short of the guide's implied pace.

Final Thoughts: Should You Invest in Aehr Test Systems in 2026?

Following its July 14 report, Aehr combines record bookings and an unusually large effective-backlog base with a fiscal 2026 revenue decline and negative operating cash flow. The $125 bull reference needs evidence that production programs can convert on schedule.

The bull case is that fiscal 2027 guidance becomes visible in quarterly revenue, delivery and non-GAAP profitability. The bear case is that qualification or installation timing moves out and prevents the expected conversion. The next financial reports provide the clearest confirmation point for either view.

Risk Reminder: Trading and investing in AEHR involves a high risk of capital loss. AEHR-USDT perpetual exposure adds leverage, funding and liquidation risk. Conduct independent research before allocating capital.